![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Vanessa Taieb, Maud Pacou, Sophia Ho, Ségolène Pettré, Suzy Van Sanden, Marta Pisini, Andrew Ustianowski & Angelika Mehnert. (2015) A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus. Journal of Medical Economics 18:10, pages 787-796.
Read now
Read now
Eric Druyts, Kristian Thorlund & Edward J. Mills. (2014) Letter to the Editor. Journal of Medical Economics 17:7, pages 445-445.
Read now
Read now
Sandrine Cure, Florence Bianic, Sandra Gavart, Steve Curtis, Seina Lee & Geoffrey Dusheiko. (2014) Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. Journal of Medical Economics 17:1, pages 65-76.
Read now
Read now
Eric Druyts, Kristian Thorlund, Samantha Humphreys, Michaela Lion, Curtis L Cooper & Edward J Mills. (2013) Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clinical Epidemiology 5, pages 173-183.
Read now
Read now
Articles from other publishers (9)
Koichi Ando, Akihiko Tanaka & Hironori Sagara. (2020) Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review. International Journal of Molecular Sciences 21:3, pages 889.
Crossref
Crossref
Zhi-qiang Cai, Peng Guo, Shu-bin Si, Zhi-min Geng, Chen Chen & Long-long Cong. (2017) Analysis of prognostic factors for survival after surgery for gallbladder cancer based on a Bayesian network. Scientific Reports 7:1.
Crossref
Crossref
Helena H. Borba, Astrid Wiens, Laiza M. Steimbach, Cassio M. Perlin, Fernanda S. Tonin, Maria L. A. Pedroso, Fernando Fernandez-Llimos & Roberto Pontarolo. (2016) Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. European Journal of Clinical Pharmacology 73:1, pages 1-14.
Crossref
Crossref
Onur Baser, Akif Altinbas, Erdem Baser & M. Furaha Kariburyo. (2015) Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey. Value in Health Regional Issues 7, pages 42-48.
Crossref
Crossref
Zhi-qiang Cai, Shu-bin Si, Chen Chen, Yaling Zhao, Yong-yi Ma, Lin Wang & Zhi-min Geng. (2015) Analysis of Prognostic Factors for Survival after Hepatectomy for Hepatocellular Carcinoma Based on a Bayesian Network. PLOS ONE 10:3, pages e0120805.
Crossref
Crossref
Aikaterini Vellopoulou, Michel van Agthoven, Annemarie van der Kolk, Robert J. de Knegt, Gilles Berdeaux, Sandrine Cure, Florence Bianic & Mark Lamotte. (2014) Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. Applied Health Economics and Health Policy 12:6, pages 647-659.
Crossref
Crossref
Nicola Coppola, Mariantonietta Pisaturo, Caterina Sagnelli, Evangelista Sagnelli & Italo F. Angelillo. (2014) Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS ONE 9:4, pages e94542.
Crossref
Crossref
C. Park, S. Jiang & K. A. Lawson. (2014) Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics 39:1, pages 14-24.
Crossref
Crossref
Delphine Bonnet. (2014) Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World Journal of Hepatology 6:9, pages 660.
Crossref
Crossref